<DOC>
	<DOC>NCT01767155</DOC>
	<brief_summary>Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin. The study will include about 500 patients with endometrial cancer resistant to platinum/taxane-based chemotherapy.</brief_summary>
	<brief_title>Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1. Women â‰¥ 18 years of age 2. Histologically confirmed endometrial cancer 3. Advanced (FIGO stage III or IV), recurrent or metastatic disease. 4. Measurable or nonmeasurable disease that has progressed since last treatment. 5. 5. Patients with advanced, recurrent or metastatic endometrial cancer who have received one chemotherapeutic regimen with platinum and taxane (either as adjuvant or as first line treatment) and who have progressed. 6. Availability of fresh or archival FFPE tumor specimens for analysis of LHRH receptor expression. 1. ECOG performance status &gt; 2. 2. Inadequate hematologic, hepatic or renal function 3. Red blood cell transfusion within 2 weeks prior to anticipated start of study treatment. 4. History of myocardial infarction, acute inflammatory heart disease, unstable angina, or uncontrolled arrhythmia within the past 6 months. 5. Impaired cardiac function defined as left ventricular ejection fraction (LVEF) &lt; 50 % (or below the study site's lower limit of normal) as measured by MUGA or ECHO. 6. Concomitant use of prohibited therapy (specified in protocol) 7. Chemo, immune, or hormonetherapy within 5 elimination half life times or 4 weeks prior to randomization, whichever is the shorter. Radiotherapy (including pre or postoperative brachytherapy) within 4 weeks prior to randomization. 8. Previous anthracyclinebased chemotherapy (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone and valrubicin), in any formulation. 9. Anticipated ongoing concomitant anticancer therapy during the study. 10. History of serious comorbidity or uncontrolled illness that would preclude study therapy, such as active tuberculosis or any other active infection. 11. Brain metastasis, leptomeningeal disease. 12. Pregnant or lactating female or female of childbearing potential not employing adequate contraception. 13. Subjects with known hypersensitivity to peptide drugs, including LHRH agonists. 14. Receipt of 2 or more prior cytotoxic chemotherapy regimens for advanced, recurrent, or metastatic endometrial cancer. 15. Prior treatment with AEZS108. 16. Use of LHRH agonist or antagonist treatment within 6 months prior to randomization. 17. Malignancy within last 5 years except nonmelanoma skin cancer. 18. Any concomitant disease or condition which would interfere with the subjects' proper completion of the protocol assignment. 19. Concomitant or recent treatment with other investigational drug (within 4 weeks or 5 elimination half life times prior to anticipated start of study treatment). 20. Lack of ability or willingness to give informed consent. 21. Anticipated nonavailability for study visits/procedures.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>